Cancer risk in users of calcium channel blockers
Cancer risk in users of calcium channel blockers
复制标题
DOI：
10.1161/01.hyp.29.5.1091
复制
发表时间：
1997-05-01
期刊：
影响因子：
8.3
通讯作者：
Olsen, J
中科院分区：
文献类型：
--
作者：
Olsen, JH;Sorensen, HT;Olsen, J
Ca2+通道阻断剂可能通过抑制细胞凋亡或减少某些组织中的细胞内Ca2+而导致癌症。最近的研究结果表明，吸毒者患癌症的风险普遍增加，尤其是结肠癌。我们进行了一项研究，在丹麦的一个县的17911例患者接受了至少一个处方的钙离子通道阻滞剂之间的1991年1月1日和1993年12月31日。这些患者是从国家健康保险计划的记录中确定的，该计划退还了此类药物的部分价格。癌症的发生率和发病率是通过使用丹麦癌症登记处的文件来确定的，并与不同类型癌症的县特定发病率进行比较。在长达3年的随访期间，在使用钙通道阻滞剂的患者中观察到412例癌症，而预期为414例，得出年龄和性别标准化发病率比（SIR）为1.00（95%置信区间为0.90至1.10）。没有迹象表明可能长期使用者或特定药物使用者亚组存在过度风险。在34例病例的基础上，结肠癌的SIR为0.8（95%置信区间，0.5至1.1）。虽然结果令人放心，但缺乏相关性可能反映了在处方数据库中注册后的随访时间相对较短。计划继续监测癌症风险。
Ca2+ channel blockers may cause cancer by inhibiting apoptosis or reducing intracellular Ca2+ in certain tissues. Recent findings suggest that drug users are at increased risk for cancer in general and for colon cancer in particular. We conducted a study in one Danish county of 17 911 patients who received at least one prescription of Ca2+ channel blockers between 1 January 1991 and 31 December 1993. The patients were identified from records in the National Health Insurance Program, which refunds part of the price of such drugs. Cancer occurrence and rate were determined by use of the files of the Danish Cancer Registry and compared with county-specific incidence rates for various categories of cancer. During the follow-up period of up to 3 years, 412 cancers were observed among users of Ca2+ channel blockers, compared with 414 expected, to yield an age- and sex-standardized incidence ratio (SIR) of 1.00 (95% confidence interval, 0.90 to 1.10). There was no indication of an excess risk in the subgroup of likely long-term users or users of specific drugs. The SIR of colon cancer, a site of a priori interest, was 0.8 (95% confidence interval, 0.5 to 1.1) on the basis of 34 cases. Although the results are reassuring, the lack of association could reflect the relatively short follow-up after registration in the prescription database. Continued monitoring of cancer risk is planned.